CN101411717A - 一种治疗急性肠炎和痢疾的组合物 - Google Patents

一种治疗急性肠炎和痢疾的组合物 Download PDF

Info

Publication number
CN101411717A
CN101411717A CNA2008102259585A CN200810225958A CN101411717A CN 101411717 A CN101411717 A CN 101411717A CN A2008102259585 A CNA2008102259585 A CN A2008102259585A CN 200810225958 A CN200810225958 A CN 200810225958A CN 101411717 A CN101411717 A CN 101411717A
Authority
CN
China
Prior art keywords
parts
dysentery
portions
jateorhizine
berberine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008102259585A
Other languages
English (en)
Other versions
CN101411717B (zh
Inventor
张贵君
罗立宇
崔向微
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING HONGTAI KANGDA PHARMACEUTICAL TECHNOLOGY Co Ltd
Original Assignee
BEIJING HONGTAI KANGDA PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING HONGTAI KANGDA PHARMACEUTICAL TECHNOLOGY Co Ltd filed Critical BEIJING HONGTAI KANGDA PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority to CN2008102259585A priority Critical patent/CN101411717B/zh
Publication of CN101411717A publication Critical patent/CN101411717A/zh
Priority to PCT/CN2009/001034 priority patent/WO2010051683A1/zh
Application granted granted Critical
Publication of CN101411717B publication Critical patent/CN101411717B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种治疗急性肠炎和痢疾的组合物，各种成分的重量份数比为：葛根素20－70份，黄豆苷1－20份，黄芩苷1－20份，小檗碱1－30份，巴马汀1－10份，药根碱1－10份，甘草酸1－15份，甘草苷1－15份。本发明的组合物可以制为片剂、口服液、颗粒剂、硬胶囊剂、软胶囊剂、滴丸剂或丸剂，服用方便，起效快，效果显著。

Description

一种治疗急性肠炎和痢疾的组合物
技术领域
本发明涉及一种治疗急性肠炎和痢疾的组合物，属于中药技术领域。
背景技术
急性肠炎又称急性胃肠炎，是夏秋季的常见病、多发病。是由于食进含有病原菌及其毒素的食物，或饮食不当，如过量的有刺激性的不易消化的食物而引起的胃肠道粘膜的急性炎症性改变。主要表现为恶心、呕吐、腹痛、腹泻；发热等，严重者可致脱水、电解质紊乱、休克等。病人多表现为恶心、呕吐在先；继以腹泻，每日3—5次甚至数十次不等，大便多呈水样，深黄色或带绿色，恶臭，可伴有腹部绞痛、发热、全身酸痛等症状。
痢疾，古称肠辟、滞下。为急性肠道传染病之一。中医认为，本病多因外受湿热、疫毒之气，内伤饮食生冷，损伤脾胃及脏腑而成，属于“肠辟、痢疾”范畴。《素问·太阴阳明论》云：“饮食不节，起居不时......下为飨泄，久为肠辟。”，《证治汇补》指出：“肠辟者，谓湿热积于肠中.即今痢疾也，故曰无疾不成痢，痢乃湿、热、食积三者”。在治疗上应采取辨证论治的方法，《景岳全书》云：“凡治痢疾，最当察虚实，辨寒热，此泻痢最大关系，若四者不明，则杀人甚易也。”，故本病辨证首辨寒、热、虚、实，临证当据腹痛、里急后重、痢色，并参合舌脉而辨，临床以发热、腹痛、里急后重、大便脓血为主要症状。若感染疫毒，发病急剧，伴突然高热，神昏、惊厥者，为疫毒痢。痢疾初起，先见腹痛，继而下痢，日夜数次至数十次不等。多发于夏秋季节，由湿热之邪，内伤脾胃，致脾失健运，胃失消导，更挟积滞，酝酿肠道而成。
发明内容
本发明所要解决的技术问题在于，提供一种治疗急性肠炎和痢疾，疗效确切的组合物制剂。
为解决上述技术问题，本发明公开了一种治疗急性肠炎和痢疾的组合物，其特征在于，由下列成分重量份数比制成：葛根素20-70份，黄豆苷1-20份，黄芩苷1-20份，小檗碱1-30份，巴马汀1-10份，药根碱1-10份，甘草酸1-15份，甘草苷1-15份。
所述治疗急性肠炎和痢疾的组合物，各成分的重量份数比还可以为：葛根素30-60份，黄豆苷5-15份，黄芩苷5-15份，小檗碱2-8份，巴马汀3-8份，药根碱2-9份，甘草酸3-13份，甘草苷4-13份。
所述治疗急性肠炎和痢疾的组合物，各成分的重量份数比还可以为：葛根素40-50份，黄豆苷8-13份，黄芩苷7-12份，小檗碱3-7份，巴马汀4-7份，药根碱3-6份，甘草酸5-11份，甘草苷6-12份。
所述治疗急性肠炎和痢疾的组合物，各成分的重量份数比为：葛根素45份，黄豆苷11份，黄芩苷9份，小檗碱5份，巴马汀6份，药根碱4份，甘草酸8份，甘草苷9份。
以上所述治疗急性肠炎和痢疾的组合物，其特征在于，所述组合物制成片剂、口服液、颗粒剂、硬胶囊剂、软胶囊剂、滴丸剂或丸剂。
以上所述的组合物，用于治疗急性肠炎和痢疾的药物用途。
本发明的组合物疗效确切，外解肌表之邪以散热.，内清阳明之热，升发脾胃清阳之气止泻生津，厚肠止痢。
具体实施方式
实施例一：一种治疗急性肠炎和痢疾，疗效确切的组合物，各成分的重量份数比为葛根素45份，黄豆苷11份，黄芩苷9份，小檗碱5份，巴马汀6份，药根碱4份，甘草酸8份，甘草苷9份。
病例1：冯女士，27岁，主诉症状为：恶心呕吐，继以腹泻多次，大便多呈水样，恶臭，伴有腹部绞痛，全身酸痛，诊断为急性肠炎。
治疗：使用本发明制成的颗粒剂，2天后见效，腹泻症状减轻，继续服用4天，症状完全消失。
实施例二：本发明组合物配方还可以按以下重量份数比：葛根素70份，黄豆苷20份，黄芩苷20份，小檗碱30份，巴马汀10份，药根碱10份，甘草酸15份，甘草苷15份。
病例2：杨先生，20岁，主诉症状为：发烧，体温达39℃，伴有恶心呕吐，腹痛腹泻症状，大便每日10次以上，初为稀便，继呈脓血便，左下腹压痛伴肠鸣音亢进，里急后重明显。临床诊断为痢疾。
治疗：使用本发明制成的滴丸剂，3天后见效，腹泻症状减轻，便血基本消失，继续服用6天后，症状完全消失。
实施例三：本发明组合物配方还可以按以下重量份数比：葛根素20份，黄豆苷1份，黄芩苷1份，小檗碱1份，巴马汀1份，药根碱1份，甘草酸1份，甘草苷1份。
病例3赵先生，42岁，主诉症状为：发烧，体温高达40℃，呕吐，腹痛，里急后重明显，排脓血便，每日达数10次，并出现脱水症状，临床诊断为重型痢疾。
治疗：使用本发明制成的口服液，2天后见效，腹痛减轻，停止呕吐，继续服用6天后，便血消失，排便次数减少至3～4次，症状减轻，继续服用6天后症状完全消失。
实施例四：本发明组合物配方还可以按以下重量份数比：葛根素50份，黄豆苷15份，黄芩苷10份，小檗碱10份，巴马汀6份，药根碱5份，甘草酸7份，甘草苷6份。
实施例4李女士，34岁，主诉症状为：呕吐，腹痛，里急后重明显，大便多呈水样，深黄色，每日达数4次，临床诊断为急性肠炎。
治疗：使用本发明制成的硬胶囊，服用2天，症状减轻，排便次数减少至2次，服用7天后，症状消失。

Claims (6)

1.一种治疗急性肠炎和痢疾的组合物，其特征在于，由下列成分重量份数比制成：葛根素20-70份，黄豆苷1-20份，黄芩苷1-20份，小檗碱1-30份，巴马汀1-10份，药根碱1-10份，甘草酸1-15份，甘草苷1-15份。
2.根据权利要求1所述组合物，其特征在于，由下列成分重量份数比制成：葛根素30-60份，黄豆苷5-15份，黄芩苷5-15份，小檗碱2-8份，巴马汀3-8份，药根碱2-9份，甘草酸3-13份，甘草苷4-13份。
3.根据权利要求1所述组合物，其特征在于，由下列成分重量份数比制成：葛根素40-50份，黄豆苷8-13份，黄芩苷7-12份，小檗碱3-7份，巴马汀4-7份，药根碱3-6份，甘草酸5-11份，甘草苷6-12份。
4.根据权利要求1所述组合物，其特征在于，由下列成分重量份数比制成：葛根素45份，黄豆苷11份，黄芩苷9份，小檗碱5份，巴马汀6份，药根碱4份，甘草酸8份，甘草苷9份。
5.根据权利要求1-4中任一项所述的组合物，其特征在于，所述组合物制成片剂、口服液、颗粒剂、硬胶囊剂、软胶囊剂、滴丸剂或丸剂。
6.权利要求1-4中任一项所述的组合物在制备治疗急性肠炎和痢疾的药物中的应用。
CN2008102259585A 2008-11-07 2008-11-07 一种治疗急性肠炎和痢疾的组合物 Expired - Fee Related CN101411717B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2008102259585A CN101411717B (zh) 2008-11-07 2008-11-07 一种治疗急性肠炎和痢疾的组合物
PCT/CN2009/001034 WO2010051683A1 (zh) 2008-11-07 2009-09-15 一种治疗急性肠炎和痢疾的组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008102259585A CN101411717B (zh) 2008-11-07 2008-11-07 一种治疗急性肠炎和痢疾的组合物

Publications (2)

Publication Number Publication Date
CN101411717A true CN101411717A (zh) 2009-04-22
CN101411717B CN101411717B (zh) 2010-10-13

Family

ID=40592596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008102259585A Expired - Fee Related CN101411717B (zh) 2008-11-07 2008-11-07 一种治疗急性肠炎和痢疾的组合物

Country Status (2)

Country Link
CN (1) CN101411717B (zh)
WO (1) WO2010051683A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105079223A (zh) * 2015-08-10 2015-11-25 陈彬 一种治疗寒湿阻滞型急性肠炎的中药组合物及其制备方法
CN106619682A (zh) * 2016-12-23 2017-05-10 郑州仁宏医药科技有限公司 一种治疗猪腹泻的药物组合物
CN106963777A (zh) * 2017-04-14 2017-07-21 宁夏医科大学 一种“黄芩苷‑小檗碱”复合物的制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579439A (zh) * 2012-03-23 2012-07-18 重庆康刻尔制药有限公司 一种黄藤素组合药物、胶囊剂、制备方法及其应用
AU2018241231A1 (en) * 2017-03-28 2019-11-07 IRP Health Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
CN117298131B (zh) * 2023-11-29 2024-02-23 唐宁医药科技(济南)有限公司 一种用于糖尿病足的甘草酸-药根碱纳米药物、制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232258C (zh) * 2003-01-14 2005-12-21 吉林天药科技股份有限公司 一种抗感染药物
CN101156906B (zh) * 2007-10-12 2011-11-30 南方医科大学 一种葛根芩连药物组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105079223A (zh) * 2015-08-10 2015-11-25 陈彬 一种治疗寒湿阻滞型急性肠炎的中药组合物及其制备方法
CN106619682A (zh) * 2016-12-23 2017-05-10 郑州仁宏医药科技有限公司 一种治疗猪腹泻的药物组合物
CN106963777A (zh) * 2017-04-14 2017-07-21 宁夏医科大学 一种“黄芩苷‑小檗碱”复合物的制备方法及其应用
CN106963777B (zh) * 2017-04-14 2020-07-14 宁夏医科大学 一种“黄芩苷-小檗碱”复合物的制备方法及其应用

Also Published As

Publication number Publication date
CN101411717B (zh) 2010-10-13
WO2010051683A1 (zh) 2010-05-14

Similar Documents

Publication Publication Date Title
CN102698123B (zh) 治疗猪传染性胃肠炎的中药组合物、饲料、制备和应用
CN101411717B (zh) 一种治疗急性肠炎和痢疾的组合物
CN101439164B (zh) 一种治疗实火型口疮的中药制备方法
CN102631592A (zh) 一种治疗脓血型结肠炎的中药制备方法
CN104548015B (zh) 一种治疗慢性结肠炎的药物
CN100352463C (zh) 一种治疗小儿腹泻的中药复方制剂及其制备方法
CN102451268B (zh) 一种治疗幽门螺杆菌相关性胃病的中药制剂及制备方法
CN104474204A (zh) 一种治疗小儿泄泻的药物组合物
CN101757083B (zh) 含有木香烯内酯的治疗胃肠疾病中药组合物及其制备方法
CN101455772B (zh) 一种治疗胃热型急性乳腺炎的中药制备方法
CN105832991A (zh) 一种治疗胃炎的中药组合物
CN101700296B (zh) 一种治疗肠胃炎的中药制剂及其制备方法
CN103356880A (zh) 一种促进胃肠动力的中成药及其制备方法
CN103719616B (zh) 用于治疗猪血痢的饲料及其制备方法
CN1060390C (zh) 幽门螺杆菌相关性胃病用中药
CN106619745A (zh) 治疗胃肠疾病的生物菌液及其制备方法
CN105770074A (zh) 一种治疗风热感冒的中药组合物及其制备方法
CN101926954A (zh) 治疗慢性结肠炎的灌肠汤剂
CN1088378C (zh) 治疗慢性浅表性胃炎的中药口服液及其制备方法
CN102000295B (zh) 一种用于治疗胃炎、胃溃疡的中药制剂及其制备方法
CN100586451C (zh) 治疗慢性溃疡型结肠炎的地锦草口服液及其制备方法
CN103751599A (zh) 一种治疗肝火犯肺型高脂血症的中药制备方法
CN103479915A (zh) 一种治疗急性肾炎的中药组合物及其制备方法
CN105535904A (zh) 一种治疗慢性阿米巴痢疾的中药制剂
CN101579340A (zh) 一种治疗胃肠炎、胃溃疡的复方药剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
DD01 Delivery of document by public notice
DD01 Delivery of document by public notice

Addressee: Beijing Hongtai Kangda Pharmaceutical Technology Co., Ltd.

Document name: Notification to Pay the Fees

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101013

Termination date: 20171107